Table 1.

Tenofovir and tenofovir diphosphate C_24h concentrations achieved in pharmacokinetic studies of oral TDF and tenofovir 1% vaginal gel

Analyte	Tissue	Oral TDF 300	Ref	Tenofovir 1% vaginal gela	Reference
TFV	Blood plasma	41 (34–47) ng/mL	32	0.3 (0.3,0.5) ng/mL	35
	CVF	69 (57–586) ng/mL	32	100000 ng/mL	35
		68.4 (28.2–112.6) ng/mLb	33
		84.03 (95% CI 24.47–288.56) ng/mLb	34
	Vaginal tissue	6.8 ng/g	32	7000 ng/g	35
	Cervical tissue	50 ng/g	32
	Rectal tissue	1877 ng/g	32
TFV-DP	Vaginal tissue	1645 fmol/g	32
	Cervical tissue	BLQ	32
	Endocervical cells			80,000 ng/mL	35
	Rectal tissue	206950 fmol/g	32

Notes: All data are median (interquartile range) unless otherwise indicated.

^aData shown are for single dose gel applications;

^bthese results were obtained in HIV-infected women on antiretroviral therapy; all other data are from healthy volunteers.

Abbreviations: BLQ, below the limit of quantification; CVF, cervicovaginal fluid; HIV, human immunodeficiency virus; TDF, tenofovir disoproxil fumarate; TFV-DP, tenofovir diphosphate.